Takeda Pharmaceutical Company Limited

Most Recent

  • uploads///pharma challenges Japan
    Company & Industry Overviews

    What Are the Challenges for the Pharmaceutical Industry in Japan?

    Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

    By Jillian Dabney
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///salix
    Company & Industry Overviews

    What Might Have Fueled Valeant’s Interest in Salix?

    The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

    By Jillian Dabney
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///Xtandi
    Company & Industry Overviews

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    How Pfizer’s Sutent and Xalkori Have Performed

    In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.

    By Margaret Patrick
  • uploads///Imbruvica
    Company & Industry Overviews

    A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

    Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

    By Daniel Collins
  • uploads///revlimid
    Earnings Report

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

    By Daniel Collins
  • uploads///Shire
    Miscellaneous

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

    By Kenneth Smith
  • uploads///Remicade
    Company & Industry Overviews

    Performance of Johnson & Johnson’s Remicade and Stelara in 2017

    In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.

    By Daniel Collins
  • uploads///Bosulif
    Company & Industry Overviews

    Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017

    In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Tasigna
    Company & Industry Overviews

    Tasigna Could Boost Novartis’s Revenue Growth in 2018

    In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.

    By Daniel Collins
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Alecensa
    Company & Industry Overviews

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

    By Daniel Collins
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

    By Kenneth Smith
  • uploads///Nexium
    Company & Industry Overviews

    How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017

    In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

    By Daniel Collins
  • uploads///Amitiza performance
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017

    Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

    By Kenneth Smith
  • uploads///Pipeline
    Company & Industry Overviews

    Amgen’s Pipeline Could Boost Its Long-Term Growth Opportunities

    EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

    By Daniel Collins
  • uploads///Gleevec tasigna
    Company & Industry Overviews

    How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?

    In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Revlimid revenues
    Company & Industry Overviews

    Celgene’s Revlimid Witnessed High Growth in 2Q17

    In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Lupron Revenues
    Company & Industry Overviews

    Why Lupron Could Continue to Generate Steady Revenue

    In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

    By Daniel Collins
  • uploads///Kyprolis Clinical Trial Result
    Company & Industry Overviews

    Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017

    Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Xifaxan Expected to Witness Robust Growth in 2017

    Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US market. Furthermore, the authorized generic version of Zegerid was transferred from Valeant’s Branded Rx segment to the Diversified Products segment. However, these negative trends were […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Merck Continues to Dominate with Its Januvia Franchise

    Despite more competition and pressures, Merck’s Januvia franchise continued to maintain its leadership in the DPP-4 inhibitor class of diabetes drugs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Has a Targeted Strategy to Expand in Major Growth Markets

    In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

    By Margaret Patrick
  • uploads///CHC business position
    Company & Industry Overviews

    Why Is Sanofi Expanding in the CHC Space?

    Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

    By Jillian Dabney
  • uploads///Commonwealth Japan Fund
    Company & Industry Overviews

    Healthcare Stocks Save the Day for CNJFX

    Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Celgene Continues to Develop New Multiple Myeloma Drugs

    Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.

    By Margaret Patrick
  • uploads///reimbursement approval
    Company & Industry Overviews

    How Are Drugs Priced in Japan?

    The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

    By Jillian Dabney
  • uploads///New drug development and approval
    Company & Industry Overviews

    What’s the Drug Approval Process in Japan?

    The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

    By Jillian Dabney
  • uploads///Voya Japan TOPIX Index Portfolio Class A
    Company & Industry Overviews

    How Did the Voya Japan TOPIX Index Portfolio Fare in 2015?

    The Voya Japan TOPIX Index Portfolio – Class A (IJIAX) fell 0.9% in December 2015 from the previous month. In the three- and six-month periods ended December 31, the fund has risen 7.3% and fallen 4.0%, respectively.

    By David Ashworth
  • uploads///Business Model
    Company & Industry Overviews

    Mylan’s Business Model: A Key Investor Rundown

    In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

    By Seth Richards
  • uploads///Brown Advisory WMC Japan Alpha Opportunities Fund
    Macroeconomic Analysis

    How the Brown Advisory-WMC Japan Alpha Opportunities Fund Fared in September 2015

    Performance evaluation The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX) fell by 6.7% in September 2015 from the previous month. In the three- and six-month periods ending September 30, the fund fell by 13.5% and 7.7%, respectively. However, in the YTD (year-to-date) period, the fund was up by 2.9%. For all periods mentioned above except […]

    By David Ashworth
  • uploads///Portfolio Break down of the BIAJX
    Macroeconomic Analysis

    The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX): Overview

    Brown Advisory-WMC Japan Alpha Opportunities Fund doesn’t target a specific segment by market capitalization. Instead, it intends to be benchmark agnostic.

    By David Ashworth
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.